Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    New York, NY

    Search
    New York, NY
    Show Map
    Map View
    New York, NY
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      194 Clinical Paid Trials near New York, NY

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Daratumumab for Antiphospholipid Syndrome

      New York, New York
      This trial is testing if daratumumab, an IV medication, is safe for people with Anti-Phospholipid Syndrome (APS). APS patients are being studied because they may not respond well to usual treatments. Daratumumab works by helping the immune system target specific cells that might be causing issues.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Systemic Autoimmune Diseases, Active Infection, Others
      Must Be Taking:Warfarin, LMWH

      22 Participants Needed

      Avutometinib + Defactinib + Chemotherapy for Pancreatic Cancer

      New York, New York
      This trial tests a new treatment combining two experimental drugs with two existing treatments for patients with newly diagnosed pancreatic cancer. The goal is to see if this combination can safely and effectively stop cancer growth and kill cancer cells. The study focuses on patients who have not yet received any treatment. One of the existing treatments used in the trial has been important in pancreatic cancer treatment but offers only modest improvements in symptoms and survival.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Severe Lung Disease, Others
      Must Not Be Taking:MEK Inhibitors, FAK Inhibitors

      40 Participants Needed

      GV20-0251 for Cancer

      New York, New York
      This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Active Infections, Autoimmune, Others
      Must Not Be Taking:Steroids, Immunosuppressives, PD-1 Modulators

      365 Participants Needed

      STAR0602 for Advanced Cancers

      New York, New York
      This trial is testing a new drug called STAR0602 to see if it is safe and effective for treating advanced cancers with specific markers. The drug is given through an IV and aims to find and destroy cancer cells by recognizing these markers. The study will first determine the best dose and then see how well the drug works in patients.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Cardiovascular, Infection, Pregnancy, Others
      Must Not Be Taking:Immune-suppressive Drugs

      365 Participants Needed

      Family Support Program for Critical Illness

      New York, New York
      This trial tests EMPOWER, a psychological therapy designed to help family members who make medical decisions for critically ill patients in ICUs. The therapy aims to reduce grief and stress by teaching coping strategies that help people accept and manage their emotions. Researchers hope this will improve mental health outcomes and decision-making abilities for these family members.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment, Suicidal Ideation, Others

      172 Participants Needed

      Psilocybin for Quitting Smoking

      New York, New York
      This trial tests psilocybin, a compound from mushrooms, to help smokers quit. It targets smokers because past studies showed good results. Psilocybin affects brain receptors to improve mood and reduce cravings, potentially making it easier to stop smoking. Psilocybin has shown promise in previous studies for promoting long-term smoking abstinence when combined with therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Neurological Illnesses, Schizophrenia, Others
      Must Not Be Taking:Antidepressants, Antipsychotics, MAOIs, Others

      66 Participants Needed

      EP0031 for Cancer

      New York, New York
      The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Active Infection, HIV, Others
      Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers

      265 Participants Needed

      Peanut SLIT-Tablet for Peanut Allergy

      New York, New York
      This trial tests a tablet containing small amounts of peanut protein taken under the tongue. It aims to help people with peanut allergies become less sensitive to peanuts. Participants will take gradually increasing doses to see if their tolerance improves.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:4 - 65

      Key Eligibility Criteria

      Disqualifiers:Eosinophilic Esophagitis, Uncontrolled Asthma, Cardiovascular Disease, Others
      Must Not Be Taking:Systemic Corticosteroids

      192 Participants Needed

      Selinexor + Temozolomide for Recurrent Glioblastoma

      New York, New York
      This trial tests selinexor with temozolomide for patients whose brain cancer has returned. Selinexor blocks a protein that helps cancer cells grow, and temozolomide damages their DNA to kill them or stop their growth. Temozolomide is a DNA methylating drug currently used as a first-line treatment in glioblastoma therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Pregnant, Severe COVID-19, Others
      Must Not Be Taking:Bevacizumab, Dacarbazine

      97 Participants Needed

      Behavioral Intervention for Increasing Walking in Cardiovascular Disease Risk

      New York, New York
      This study is a randomized, factorial experiment using the basic Science of Behavior Change (SOBC) approach to efficiently test the effects of four distinct behavior change techniques (BCTs), goal setting, action planning, self- monitoring and feedback, thought to engage one key behavioral mechanism of action (MoA) for improving daily walking by at least 1000 steps per day in persons who have been objectively verified as sedentary and are at risk for cardiovascular disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Heart Attack, Stroke, Pregnancy, Others

      624 Participants Needed

      DYP688 for Metastatic Uveal Melanoma

      New York, New York
      This trial is testing a new drug called DYP688 to see if it can help treat patients with specific types of skin cancer that have certain genetic mutations. The study aims to find out if the drug is safe and effective in shrinking tumors in these patients.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, Active Brain Metastases, Others
      Must Not Be Taking:Anticoagulants, Chemotherapy, Immuno-oncologics

      66 Participants Needed

      TAC-001 for Solid Cancers

      New York, New York
      INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, Brain Metastases, Others

      72 Participants Needed

      Avutometinib + Adagrasib for Lung Cancer

      New York, New York
      This trial is testing a combination of two drugs, avutometinib (VS-6766) and adagrasib, in patients with a specific type of lung cancer who have not responded to previous treatments. The drugs aim to stop the cancer cells from growing by blocking the signals that tell them to multiply. Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Heart Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors, BCRP Inhibitors

      85 Participants Needed

      LAVA-1207 for Prostate Cancer

      New York, New York
      This trial tests new treatments for advanced prostate cancer that doesn't respond to standard treatments. The treatments include a new drug, an immune system booster, and a medication that helps the immune system fight cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, Uncontrolled Conditions, HIV, Others
      Must Be Taking:Androgen Deprivation Therapy

      180 Participants Needed

      DISC-0974 for Myelofibrosis

      New York, New York
      This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Hereditary Hemochromatosis, Hemoglobinopathy, Others
      Must Be Taking:JAK Inhibitors

      150 Participants Needed

      Anti-CD38 Antibody Drug (STI-6129) for Multiple Myeloma

      New York, New York
      This trial tests STI-6129, a new drug for multiple myeloma patients whose cancer has returned or not responded to other treatments. The drug is given through an IV periodically to find the best dose and check its safety and effectiveness.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, Neuropathy, Heart Failure, Others
      Must Not Be Taking:Anticoagulants

      72 Participants Needed

      Cyclophosphamide + Bortezomib + Abatacept for Graft-versus-Host Disease

      New York, New York
      This trial is testing three new treatments to prevent a complication called GvHD in adults with blood cancers receiving stem cell transplants. It targets patients at high risk of GvHD due to their transplant type. The treatments work by calming the immune system to prevent it from attacking the body.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Heart Failure, Recent Malignancy, Others

      74 Participants Needed

      BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

      New York, New York
      BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Resistant Mutations, Interstitial Lung Disease, Others
      Must Be Taking:EGFR TKIs

      200 Participants Needed

      ZN-c3 + Niraparib for Ovarian Cancer

      New York, New York
      This trial is testing a new drug called ZN-c3, alone and with niraparib, in patients with a type of ovarian cancer that doesn't respond to usual treatments. The drugs work by stopping cancer cell growth and preventing the cells from repairing themselves. Niraparib is an oral medication approved for use in ovarian cancer patients.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      117 Participants Needed

      Venetoclax + Navitoclax for Acute Lymphoblastic Leukemia

      New York, New York
      This is a phase I/II clinical trial evaluating the activity of combination chemotherapy with venetoclax and navitoclax in children with relapsed or refractory acute lymphoblastic leukemia or lymphoma (rALL) and assessing the combination dose of venetoclax combinations with either blinatumomab for CD19-positive patients or navitoclax and high-dose cytarabine for CD19-negative patients. Primary Objectives * To compare Minimal Residual Disease (MRD)-negative CR/CRi rate in children with relapsed or refractory acute lymphoblastic leukemia or lymphoma (rALL) following Block 1 therapy with venetoclax and navitoclax based reinduction to historical controls. * To identify the recommended phase 2 combination dose (RP2D) of venetoclax based consolidation in novel combinations with a) high-dose cytarabine and navitoclax or b) blinatumomab. Secondary Objectives * To estimate the tolerability and activity of venetoclax based consolidation in novel combinations with a) high-dose cytarabine and navitoclax or b) blinatumomab. * To describe event-free and overall survival in patients treated with this regimen. Exploratory Objectives * To evaluate MRD-negative CR/CRi rates in each prespecified groups: late first relapse B-ALL; early first relapse and second or greater relapse B-ALL; and relapsed T-ALL. * To identify drug sensitivity patterns in patient samples prior to and after receiving combination therapy and evaluate mechanisms of disease resistance/ escape. * To explore immune subsets during and after this regimen. * Evaluate response to therapy in rare relapse patient subsets. * Explore breakthrough infections in children and young adults with relapsed or refractory ALL
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:4 - 30

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
      Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers

      35 Participants Needed

      Why Other Patients Applied

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50
      Match to a Trial

      Lurbinectedin + Doxorubicin for Leiomyosarcoma

      New York, New York
      This trial is testing a new drug, lurbinectedin, combined with an existing chemotherapy drug, doxorubicin, in patients with advanced leiomyosarcoma. The goal is to see if this combination is safe and more effective than doxorubicin alone. Both drugs work by damaging the DNA in cancer cells, leading to their death. Lurbinectedin is a synthetic marine-derived anticancer agent that has shown promise in treating certain types of cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Disease, Cardiomyopathy, Others
      Must Not Be Taking:CYP3A Inhibitors, CYP2D6 Inducers

      62 Participants Needed

      Selinexor + Radiation for Brain Cancer

      New York, New York
      This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12 - 21

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Infection, Organ Transplant, Others
      Must Not Be Taking:Investigational Drugs, Anti-cancer Agents

      132 Participants Needed

      STK-012 + Pembrolizumab for Cancer

      New York, New York
      This trial is testing a new drug called STK-012 alone and with another medication in patients with advanced solid tumors that haven't responded to usual treatments. The aim is to find the right dose and see how well it works.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Recent Radiotherapy, IL-2/IL-15 Therapy, Others
      Must Not Be Taking:Small Molecule Inhibitors

      364 Participants Needed

      STMC-103H for Allergies

      New York, New York
      This trial is testing a new treatment called STMC-103H to see if it can help prevent allergic diseases in young children. The study focuses on babies and infants who are at risk of developing allergies. The treatment aims to improve their immune system's response to allergens, potentially reducing conditions like atopic dermatitis.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:0 - 14

      Key Eligibility Criteria

      Disqualifiers:Congenital Abnormalities, Immune Deficiency, Others
      Must Not Be Taking:Systemic Antibiotics

      264 Participants Needed

      Tipifarnib + Alpelisib for Head and Neck Cancer

      New York, New York
      This trial tests a combination of two drugs, tipifarnib and alpelisib, in patients with advanced head and neck cancer that have specific genetic changes. The drugs aim to stop cancer growth by blocking essential enzymes. Tipifarnib is a farnesyl transferase inhibitor that has shown clinical activity in head and neck squamous cell carcinoma, particularly in tumors with HRAS mutations.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Pneumonitis, Neuropathy, Others
      Must Not Be Taking:Anticancer Agents

      40 Participants Needed

      DSP-5336 for Leukemia

      New York, New York
      This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Acute Promyelocytic Leukemia, CNS Leukemia, Others
      Must Not Be Taking:Calcineurin Inhibitors, CYP3A4/5 Inhibitors

      362 Participants Needed

      REGN5093-M114 for Non-Small Cell Lung Cancer

      New York, New York
      This trial is testing a new drug alone and in combination with another treatment in patients with advanced lung cancer that has high levels of a specific protein. The goal is to see if the drug is safe and effective in stopping cancer growth and helping the immune system fight the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, Untreated Brain Tumor, Others

      30 Participants Needed

      Pembrolizumab + AR Inhibitors for Prostate Cancer

      New York, New York
      This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor inhibitor (ARI) is more effective against prostate cancer than pembrolizumab + ARI alone.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, HIV, Hepatitis, Others
      Must Be Taking:LHRH/GnRH Analogue

      76 Participants Needed

      177Lu-FAP-2286 for Solid Cancers

      New York, New York
      This trial tests a new drug, [177Lu]Lu FAP 2286, which targets a specific protein on cancer cells and delivers radiation to kill them. It focuses on patients with certain types of cancer that have this protein. The goal is to see if the drug is safe and effective.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, CNS Metastases, Cardiac Disease, Others
      Must Not Be Taking:Radiopharmaceuticals, Anticancer Drugs

      222 Participants Needed

      Botulinum Toxin + Isometric Exercises for Scoliosis

      Manhattan, New York
      This trial uses a specific yoga pose to treat adolescents with curved spines. The yoga pose strengthens weaker back muscles and helps relax stronger ones. It targets teens aged 12-18 with moderate scoliosis who may not benefit from other treatments.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:14 - 18

      Key Eligibility Criteria

      Disqualifiers:Neuromuscular Disease, Genetic Abnormalities, Pregnancy, Others

      42 Participants Needed

      1...567

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials in New York

      Anxiety Clinical Trials in New York

      Schizophrenia Clinical Trials in New York

      ADHD Clinical Trials in New York

      Bipolar Disorder Clinical Trials in New York

      Multiple Sclerosis Clinical Trials in New York

      Autism Clinical Trials in New York

      Treatment Resistant Depression Clinical Trials in New York

      Borderline Personality Disorder Clinical Trials in New York

      Social Anxiety Disorder Clinical Trials in New York

      Parkinson's Disease Clinical Trials in New York

      Alzheimer's Disease Clinical Trials in New York

      By Location

      Clinical Trials near New York, NY

      Clinical Trials near Rochester, NY

      Clinical Trials near Bronx, NY

      Clinical Trials near The Bronx, NY

      Clinical Trials near Buffalo, NY

      Clinical Trials near Brooklyn, NY

      Clinical Trials near Syracuse, NY

      Clinical Trials near Albany, NY

      Clinical Trials near Stony Brook, NY

      Clinical Trials near Manhasset, NY

      Clinical Trials near New Hyde Park, NY

      Clinical Trials near Mineola, NY

      Other People Viewed

      By Subject

      Top Clinical Trials near New York, NY

      Top Depression Clinical Trials near New York, NY

      Top Glioblastoma Clinical Trials near New York, NY

      130 Diabetes Trials near New York, NY

      Top Depression Clinical Trials near New York City, NY

      Top Prostate Cancer Clinical Trials near New York, NY

      14 Osteoporosis Trials near New York, NY

      Top Clinical Trials near New York

      Top Clinical Trials near New York

      Top Lung Cancer Clinical Trials near New York, NY

      Top Clinical Trials near Elmhurst, NY

      Top Clinical Trials near Kew Gardens, NY

      By Trial

      ChangeGradients for Adolescent Health Behaviors

      Lithium for Mild Cognitive Impairment

      Ultralow Dose PET Imaging for Dementia

      Cabergoline for Endometriosis

      New Treatments for Prostate Cancer

      New Aortic Heart Valves for Aortic Stenosis

      Family Foundations Program for New Parents

      New Antibiotics vs Linezolid for Diabetic Foot Infections

      Bladder or Combined Kidney-Bladder Transplants for Bladder Disease

      Electrophysiology-Guided Care for Left Bundle Branch Block After TAVI

      ASTX660 for Cancer

      SABR + Pentoxifylline/Vitamin E for Lung Cancer

      Related Searches

      Top Ecmo Clinical Trials

      Top Clinical Trials near San Francisco, CA

      Multiprofen-CC™ for Postoperative Pain

      Pembrolizumab + Olaparib/Pemetrexed for Non-Small Cell Lung Cancer

      TILT-123 + Pembrolizumab for Lung Cancer

      Neratinib or Neratinib + Palbociclib for Cancer

      4T Education and Care for Type 1 Diabetes

      Levonorgestrel IUS + Everolimus for Endometrial Cancer

      Exercise + Mindfulness for Bladder Cancer

      Top Clinical Trials near Iowa City, IA

      Top Clinical Trials near Lake Success, NY

      Prescribing Feedback for Reducing Prescribing Errors

      Frequently Asked Questions

      How much do clinical trials in New York, NY pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in New York, NY work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in New York, NY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New York, NY is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New York, NY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in New York, NY?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in New York, NY?

      Most recently, we added LevoCept for Birth Control, GGTA1 KO Thymokidney for Kidney Failure and EDV Nanocell Therapy + Chemotherapy for Pancreatic Cancer to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards in New York, NY?

      The clinics in New York, NY currently recognized as SuperSites are: Hapworth Research, INC in New York, New York